Hundested, Denmark

John Halstro Slashedm


Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 78(Granted Patents)


Company Filing History:


Years Active: 1998-1999

Loading Chart...
2 patents (USPTO):Explore Patents

Title: John Halstro: Pioneering Innovations in Peptide Derivatives and Insulin

Introduction: John Halstro, based in Hundested, Denmark, is a notable inventor recognized for his contributions to the field of pharmacology. With a total of two patents to his name, Halstro’s work focuses primarily on innovative peptide hormone derivatives and insulin formulations that present protracted profiles of action. His research has significant implications for therapeutic applications, particularly in the realm of diabetes treatment.

Latest Patents: John Halstro’s latest patents reflect his expertise in peptide technology. One of his patents pertains to peptide derivatives, wherein he introduces pharmacologically active modifications to parent peptide hormones. These modifications involve the incorporation of lipophilic substituents at both the N-terminal and C-terminal ends of the peptide. This innovation enhances the efficacy and longevity of hormone action, potentially revolutionizing hormone-based therapies.

The second patent, focusing on acylated insulin, extends the possibilities for human insulin derivatives. Halstro's invention offers flexibility in amino acid replacements and structural configurations that enhance insulin efficacy. By utilizing lipophilic amino acids and creating complexes with Zn²+, these derivatives provide improved metabolic control and stability, marking a significant advance in diabetic care.

Career Highlights: Halstro is associated with Novo Nordisk A/S, a global leader in diabetes care and pharmaceuticals. His role within the company signals his integral contribution to pioneering research aimed at advancing diabetes treatment options. Halstro’s patents not only leverage his innovative capabilities but also align with Novo Nordisk's mission to improve patient outcomes through research and development.

Collaborations: Throughout his career, Halstro has collaborated with esteemed colleagues, including Svend Havelund and Ib Jonassen. These partnerships have fostered an environment of innovation and multidisciplinary expertise, facilitating breakthroughs in peptide bioscience and therapeutic applications.

Conclusion: John Halstro stands out as a significant figure in the field of pharmacology, with his inventions propelling advancements in peptide and insulin therapies. His extensive work at Novo Nordisk A/S, coupled with his innovative patents, contributes to the ongoing evolution of diabetes treatment, offering hope for improved patient care and outcomes in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…